2.08
2.08 (0%)
As of Feb 14, 2025
Rafael Holdings, Inc. [RFL]
Source:
Company Overview
Rafael Holdings, Inc is a clinical stage biotechnology company dedicated to developing Trappsol Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal and progressive genetic disorder, a majority equity interest in LipoMedix Pharmaceuticals Ltd. (“LipoMedix”), a clinical stage pharmaceutical company, Barer Institute Inc. (“Barer”), a wholly-owned preclinical cancer metabolism research operation, and a majority interest in Cornerstone Pharmaceuticals, Inc.
| Country | United States |
| Headquarters | newark, new jersey |
| Phone Number | 212-658-1450 |
| Industry | finance |
| CEO | William Conkling |
| Website | www.rafaelholdings.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.1 |
| Operating Profit | $-6.6 |
| Net Income | $-5.3 |
| Net Cash | $45.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | -8,622.1 |
| Profit as % of Revenues | -0.7% |
| Profit as % of Assets | -5.9% |
| Profit as % of Stockholder Equity | -7.3% |
Management Effectiveness
| Return on Equity | -7.3% |
| Return on Assets | -6.4% |
| Turnover Ratio | 0.1% |
| EBITA | $-6.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $83 |
| Total Liabilities | $10.5 |
| Operating Cash Flow | $-5.4 |
| Investing Cash Flow | $51.1 |
| Financing Cash Flow | $-0.1 |
